249
Participants
Start Date
March 31, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
ADVAIR DISKUS™ 250/50mcg
ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
Placebo
COPD subjects-Placebo DISKUS
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Downington
GSK Investigational Site, Morgantown
GSK Investigational Site, Charlotte
GSK Investigational Site, Spartanburg
GSK Investigational Site, Gaffney
GSK Investigational Site, Union
GSK Investigational Site, Greenville
GSK Investigational Site, Birmingham
GSK Investigational Site, Jasper
GSK Investigational Site, Mobile
GSK Investigational Site, Johnson City
GSK Investigational Site, Minneapolis
GSK Investigational Site, Chesterfield
GSK Investigational Site, St Louis
GSK Investigational Site, Saint Charles
GSK Investigational Site, Sunset
GSK Investigational Site, Coeur d'Alene
GSK Investigational Site, Phoenix
GSK Investigational Site, Torrance
GSK Investigational Site, Spokane
GSK Investigational Site, San Diego
GSK Investigational Site, Hartford
GSK Investigational Site, Charleston
Lead Sponsor
GlaxoSmithKline
INDUSTRY